Tilray Brands (TLRY) Income towards Parent Company (2017 - 2026)
Tilray Brands' (TLRY) quarterly Income towards Parent Company came in at -$29.6 million in Q2 2026, up 96.73% YoY from -$15.1 million in Q2 2025, and down 17.45% on a QoQ basis from -$25.2 million in Q1 2026.
Tilray Brands (TLRY) Income towards Parent Company (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Income towards Parent Company data on file, last reported at -$29.6 million in Q2 2026.
- Quarterly Income towards Parent Company rose 96.73% year-over-year to -$29.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$96.9 million (up 94.67% YoY) and the FY2026 annual result came in at -$96.9 million, up 94.67% from the prior year.
- Income towards Parent Company slipped to -$29.6 million in Q2 2026, from -$25.2 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $177.5 million in Q2 2023 to a low of -$1.2 billion in Q1 2023.
- A 5-year average of -$200.1 million and a median of -$51.0 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company soared 147.75% — and 2025, when it tumbled 9797.92%.
- Tracing TLRY's Income towards Parent Company over 5 years: stood at -$85.1 million in 2022, then jumped by 45.71% to -$46.2 million in 2023, then sank by 84.65% to -$85.3 million in 2024, then jumped by 48.98% to -$43.5 million in 2025, then jumped by 31.89% to -$29.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$29.6 million (Q2 2026), -$25.2 million (Q1 2026), and -$43.5 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Tilray Brands | 512.75 Mn | 278.12 Mn | 90.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -29.64 Mn |
| Feb 28, 2026 | -25.23 Mn |
| Nov 30, 2025 | -43.51 Mn |
| Aug 31, 2025 | 1.51 Mn |
| May 31, 2025 | -905.20 Mn |
| Feb 28, 2025 | -793.53 Mn |
| Nov 30, 2024 | -85.28 Mn |
| Aug 31, 2024 | -34.65 Mn |
| May 31, 2024 | 9.33 Mn |
| Feb 29, 2024 | -104.98 Mn |
| Nov 30, 2023 | -46.18 Mn |
| Aug 31, 2023 | -55.86 Mn |
| May 31, 2023 | 177.54 Mn |
| Feb 28, 2023 | -1.20 Bn |
| Nov 30, 2022 | -85.06 Mn |
| Aug 31, 2022 | -65.79 Mn |
| May 31, 2022 | -371.80 Mn |
| Feb 28, 2022 | 52.48 Mn |
| Nov 30, 2021 | 5.80 Mn |
| Aug 31, 2021 | -34.60 Mn |